A 12-year-old, neutered female, domestic medium hair cat was evaluated for a nonhealing, oral mucosal ulceration. The cat had a history of idiopathic hypercalcemia that had been treated with a bisphosphonate for 41 months. Oral examination identified exposed maxillary bone adjacent to a previous extraction site. Histopathology of the exposed bone and associated mucosa was most consistent with medication-related osteonecrosis of the jaw. Treatment involved both medical and surgical interventions. Oral mucosal healing occurred after 6 months of treatment. 
| INTRODUCTION
Although medication-related osteonecrosis of the jaw (MRONJ) is a well-known adverse effect of bisphosphonate treatment in people, this is the first case report of MRONJ in a cat. Evaluation for potential risk factors before implementing bisphosphonate treatment is indicated, and serial oral examinations during treatment are imperative. Further research is needed to determine the frequency of and risk factors for MRONJ in small animal patients treated with bisphosphonates.
| CASE REPORT
A 12-year-old, neutered female, domestic medium hair cat weighing 4.2 kg was referred to a tertiary veterinary hospital for evaluation of oral ulcerations and associated mucosal inflammation. The cat had a longterm history of constipation managed by acacia fiber supplementation After no improvement in hypercalcemia with this regimen, the bisphosphonate pamidronate (1 mg/kg into 0.9% NaCl IV over 2 hours) was prescribed. Over the next 23 months, pamidronate was administered every 3-26 weeks based on serial serum calcium concentrations and relevant clinical signs, including decreased appetite and weight loss.
Furosemide administered PO (0.8 mg/kg PO q24h) was implemented approximately 15 months after pamidronate was started for attempted additional calciuresis. During the course of treatment, the pamidronate dose was gradually increased (up to 2.2 mg/kg in 0.9% NaCl IV over 2 hours) based on failure to restore normal total serum calcium concentrations. The time interval between pamidronate injections also decreased, with administration ultimately required every 4 weeks to control total serum hypercalcemia. The cat received cyproheptadine (0.5 mg/kg PO q12h) and ondansetron (0.5 mg/kg PO q12-24h) as needed for hyporexia. After 18 pamidronate injections over approximately 23 months (121.2 mg, cumulative dose; 28.9 mg/kg), the cat was changed to alendronate because of recurrence of hypercalcemia (2.5 mg/kg PO once weekly, gradually increased to 2.5 mg/kg 3 times NaCl SC q24-48h), prednisolone (0.55 mg/kg PO q12h), and high fiber prescription diets, which all are currently accepted treatments for idiopathic hypercalcemia in cats. 1 
| DISCUSSION
Bisphosphonates are a class of antiresorptive drugs used to treat numerous bone diseases in people, including osteoporosis, multiple myeloma, metastatic bone lesions, and hypercalcemia of malignancy, among others. 2 The phosphate and hydroxyl groups of bisphosphonates allow preferential binding to hydroxyapatite crystals within the bone matrix. Accumulation of bisphosphonates within the bone matrix ) . B, Exposed mandibular bone adjacent to left mandibular canine tooth (yellow solid arrows) that developed secondary to mucosal sloughing approximately 6 weeks later results in osteoclast apoptosis, decreased bone resorption, and subsequent accumulation of necrotic bone. 3 Osteonecrosis of the jaw bones is a serious adverse effect of bisphosphonates that was first described in people in 2003. 4 The American Association of Oral and Maxillofacial Surgeons (AAOMS) has since preferred the term "medication-related osteonecrosis of the jaw" (MRONJ) to include other antiresorptive and antiangiogenic drugs that also have resulted in mandibular or maxillary necrosis or both. 5 The reported prevalence of MRONJ varies widely, but overall is considered rare; incidence among osteoporosis patients ranges from 0.001% to 7%, and incidence among cancer patients ranges from approximately 0.7% to 15%. [6] [7] [8] [9] [10] The pathophysiology of MRONJ has not been definitively determined but is thought to be multifactorial. 5 The long-term inhibition of osteoclastic activity by bisphosphonates likely contributes to the characteristic osteonecrosis of MRONJ. 8 Their suppression of bone remodeling is most pronounced in areas of high bone turnover, which could explain why MRONJ occurs primarily within the alveolar bone of the mandible and maxilla. 5 Local oral risk factors, namely inflammation and infection, have been strongly implicated in the development of MRONJ. Introduction of bacteria can occur from either physiological microdamage within the oral cavity or from disruption of the oral mucosa from injury or dental procedure. duration of bisphosphonate treatment is also a key risk factor for MRONJ development in people. [5] [6] [7] 10, 15 The highest risk of MRONJ occurs after 3 or more years of treatment with zoledronate 6 and beyond 4 years of treatment for PO bisphosphonates. 5, 7 As expected, underlying primary disease also is a documented MRONJ risk factor because patients with malignancies require higher cumulative bisphosphonate doses. 8, 10 Approximately 52%-72% of patients who develop MRONJ have had ≥1 tooth extractions during bisphosphonate treatment, 6, 9, 10, 12, 13, 15 and patients who undergo a tooth extraction when on IV bisphosphonate treatment have a 33-fold higher risk of MRONJ development. 9 Furthermore, oral inflammation also is a well-recognized risk factor, with periodontal disease having been diagnosed in up to 84% of MRONJ patients. 10, 12, 13, 15 Evaluation of concurrent corticosteroid administration, which can delay wound healing by antiangiogenic or immunosuppressive effects, has produced conflicting results. 6, 15, 16 Bisphosphonates are used in veterinary practice for treatment of pain associated with skeletal neoplasia, medical management of hyperparathyroidism, and idiopathic hypercalcemia in cats. 1, [17] [18] [19] [20] [21] [22] [23] [24] [25] Information regarding adverse effects of chronic bisphosphonate use is currently very limited for dogs and cats. 17 Dogs have a bone remodeling rate similar to that of humans, and mandibular necrosis has occurred in some experimental canine models of MRONJ with months to years of bisphosphonate administration. 16, [26] [27] [28] Among these dogs, only 1 exhibited bone exposure after 3 months of high-dose zoledronate, which resolved quickly without intervention. 27 In a prospective study evaluating alendronate treatment for odontoclastic resorptive lesions in cats, no cats had gross evidence of oral bone exposure or ulcerations after 11 months of treatment. 22 Similarly, no adverse effects were reported in 3 other studies involving chronic alendronate treatment (ranging from 6 to 30 months) of idiopathic hypercalcemia in cats. [23] [24] [25] However, a dog with appendicular osteosarcoma developed oral mucosal ulceration and exposed mandibular bone after 46 consecutive monthly IV injections of zoledronate; histopathological evaluation of the mandible showed osteonecrosis, bacterial osteomyelitis, and metastatic osteosarcoma. 29 Most recently, a cat was diagnosed with bilateral patellar fractures and radiographically thickened cortices after 8 years of alendronate treatment. 30 To our knowledge, ours is the first case report of osteonecrosis secondary to bisphosphonate treatment in a cat. In people, MRONJ is defined by the following: current or previous treatment with antiresorptive or antiangiogenic agents, exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for >8 weeks, and no history of radiation treatment to the jaws or obvious metastatic disease to the jaws. 5 The cat of our study fulfilled these criteria and had histological evidence of osteonecrosis on maxillary bone biopsy. Alendronate has been shown to accumulate in high concentrations within the trabecular bone of cats, and its plasma half-life has been estimated for this species. 22 However, the biological half-life of bisphosphonates in cats currently is unknown. The biological half-life of bisphosphonates in people is estimated to exceed 10 years, whereas the estimated half-life in dogs is approximately 3 years. 34 If the bisphosphonate half-life in cats is similar to dogs or people, this patient could have had ongoing bisphosphonate release secondary to natural bone remodeling contributing to its 14 months of normocalcemia after discontinuation of bisphosphonate treatment.
Concerns regarding potential development and prevention of MRONJ in companion animals undergoing bisphosphonate treatment recently were reviewed. 35 Our case report, in addition to the recent case report of mandibular osteonecrosis in a dog secondary to zoledronate treatment, 29 confirms that MRONJ is a possible complication of long-term bisphosphonate use in small animal patients. A substantial decrease in MRONJ frequency occurs in people when dental hygiene is optimized before bisphosphonate initiation, 6, 36, 37 and full dental cleaning, dental radiographs, and complete healing of any extraction sites are strongly recommended before starting bisphosphonate treatment. 5, 8 Similar recommendations should be considered in veterinary patients before starting bisphosphonate treatment to maximize oral health and decrease the risk of MRONJ development.
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